Synaptogenix, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

BTS

5 Jun 2026

SNPX

10-K/A: Tao Synergies Inc. Files 10-K/A for Audit Correction

Tao Synergies Inc. filed an amendment to its 2025 Annual Report to correct the auditor's description of a critical audit matter regarding preferred stock derivative liabilities.

BTS

31 Mar 2026

SNPX

Synaptogenix, INC

10-K: TAO Synergies Pivots to AI Crypto, Reports $10.5M Digital Asset Loss

TAO Synergies Inc. has shifted its core business from biopharmaceutical development to a cryptocurrency treasury strategy focused on Bittensor's TAO token, reporting a significant unrealized loss on digital assets for 2025.

BTS

27 Mar 2025

SNPX

Synaptogenix, INC

10-K: Synaptogenix Reports 2024 Results, Focuses on Strategic Alternatives

Synaptogenix reports its 2024 financial results and continues to explore strategic options to enhance shareholder value, including evaluating drug development platforms and new technologies.

BTS

1 Apr 2024

SNPX

Synaptogenix, INC

10-K: Synaptogenix 2023 10-K Filing: Detailed Analysis of Financials, Clinical Trials, and Strategic Investments

Synaptogenix's 2023 10-K filing details its financial status, ongoing clinical trials, strategic investments, and risk factors, highlighting a year of significant activity and challenges.